Navigation Links
Kibow Biotech Achieves Major Victory with India's IPAB Decision to Uphold 2009 Product Patent
Date:12/2/2013

d with the contention of Kibow that "the invention covers a new and inventive composition comprising at least one probiotics bacteria of a certain kind, in a certain composition and along with other additives (such as vitamins, etc.) that confer synergistic impact, enabling the augmentation of kidney function". The company's management and its research and development team are fully convinced and believe that "by no stretch of imagination can this unique composition be labeled as mere admixture."

Patents covering the product/process formulation on the probiotic dietary food supplement formulation have already been obtained in Australia, Canada, China, Japan, and Korea, and are pending in the European Union. Kibow Biotech is represented in India by a leading Delhi-based IP law firm, Obhan and Associates, www.obhanandassociates.com   

About Kibow Biotech:  Founded in Oct 1, 1997 in Philadelphia, Kibow Biotech specializes in research, development and commercialization of probiotic dietary supplements adhering to US FDA and FTC regulations. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health and other healthcare applications. The Company's flagship product, Renadyl™, is currently marketed in the U.S. and Canada, and will progressively be made available worldwide, according to individual countries' governmental rules and regulatory authorities.

For further information, contact:
Natarajan Ranganathan, PhD
Managing Director 
1 (610) 353-5130

Read more news from

SOURCE Kibow Biotech
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Future of Pre- and Probiotics to be Discussed by Kibow Biotech Founder During SupplySide MarketPlace 2013 Global Expo & Conference
2. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
3. Puma Biotechnology Announces Completion of Private Placement
4. Animal Biotechnology - Technologies, Markets and Companies
5. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
6. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
7. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
8. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
9. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
10. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
11. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... SAO PAULO , June 2, 2015   ... leader in biosimilars, today announced that its partner, Celltrion – ... ANVISA – the National Health Surveillance Agency in ... first biosimilar monoclonal antibody approved for use in ... by Hospira. Hospira also markets and sells biosimilar infliximab ...
(Date:6/2/2015)... LOUIS , June 2, 2015   ... Life Science and Technology company, announced today it ... Science to launch genetically engineered human neural ... advance the research of neurological diseases. These new ... provide unique and versatile tools for the study ...
(Date:6/2/2015)... June 02, 2015 Through rare discovery ... Yancy Corporation is enabling World Scientists to ... and biological sample, displaying the full nature (position, shape, ... atoms. , Jeff Porter, Co-Founder of the Yancy Corporation, ... that – rare. They come once in a lifetime, ...
(Date:6/1/2015)... June 1, 2015  Turing Pharmaceuticals AG announced that ... Salinas , MD, MSc,  has joined the company ... Dr. Salinas, who holds a medical degree as ... record of significant accomplishments in the pharmaceutical industry, ... Dr. Salinas has played a leadership role in ...
Breaking Biology Technology:ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 3Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3
... CRANBURY, N.J., Aug. 12 Palatin Technologies, Inc. (NYSE ... of a Phase 1 clinical trial of subcutaneously administered ... male erectile dysfunction (ED) and female sexual dysfunction (FSD). ... blood plasma levels can be obtained without blood pressure ...
... Health care jobs continue ... industry remains at 20,000 monthly, and health care has one of the the lowest unemployment rates ... feeling the economic pinch more and more. , ... (Vocus) August 12, 2009 -- There is a dichotomy between simultaneous job creation and job ...
... Scientists drew fittingly from Roman mythology when they named ... Janus, who is usually depicted as having two faces ... been fascinated by the tantalizing possibilities of these particles ... and many other devices. However, realizing these applications requires ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 2Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 3Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 4The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 2The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 3The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 4Capping a two-faced particle gives duke engineers complete control 2
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... Through the generous support of the Breast ... Cancer Research (AACR) is pleased to announce the ... Translational Breast Cancer Research. These grants provide ... designed to accelerate the discovery, development, and application ...
... DC Some nanotechnology fanciers suggest that, like ... will flock or clump together. ... risks as nanotechnology manufacturing increases and the number ... nanoparticle expert Andrew Maynard, chief science advisor to ...
... A modified plastic material greatly improves the ability to ... the gas is prepared for use, according to engineers ... analyzed the new plastics performance. Like a sponge ... permits carbon dioxide or other small molecules to go ...
Cached Biology News:AACR, BCRF award inaugural grants in translational breast cancer research 2AACR, BCRF award inaugural grants in translational breast cancer research 3Nanoparticle exposures happen, says expert 2New membrane strips carbon dioxide from natural gas faster and better 2New membrane strips carbon dioxide from natural gas faster and better 3
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Phosphorylcholine hapten is conjugated to BSA protein by use of p-diazonium phenylphosphorylcholine....
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Blue Standard is 3-cyano-7-hydroxycoumarin....
Biology Products: